Prescient Therapeutics Investor Briefing – 17 March
Prescient Therapeutics (ASX: PTX) is focused on developing novel, personalised therapies for a range of cancers. Prescient’s universal
Webcast
Cancer Research
News
Prescient Therapeutics unveils three new development programs
Australian clinical stage biotech company Prescient Therapeutics (ASX: PTX) will undertake three internal development programs to advance its
News
Ain’t no mountain high enough: Cancer survivor eyes Mt. Everest after revolutionary treatment
Following more than a decade of treatments, cancer survivor Laurie Adami now plans to tackle the world’s tallest
News
How Noxopharm spent a pandemic-plagued 2020 leading the fight against cancer
Amid the tragedy of 2020’s global COVID-19 pandemic, it’s easy to forget the horrors inflicted on hundreds of
News
CAR-T Super Girl
Laurie Adami has had a long and intricate journey with blood cancer, after being diagnosed with Non-Hodgkin Lymphoma
News
Is “next-gen” CAR-T the beginning of the end of cancer?
Cancer is a word we all dread to hear yet a cure for the deadly disease has always
News
Prescient ushers in “next gen” immunotherapy cancer platform
ASX listed biotech company Prescient Therapeutics (ASX: PTX) has this week unveiled two significant licence agreements that forms
News
Successful treatments for cancer have never been more important
It is impossible to overstate the unprecedented disruptions the world is facing with COVID-19. Stock markets have plunged